highly potent and selective PPAR-α agonist known as LY518674 in patients with lipid disorders. In the first study, 309 patients with atherogenic dyslipidemia (mean age 54.2 years, 68.9% men ...

The following is a summary of “Metabolic complications and clinical outcomes of non-functioning adrenal incidentalomas: a ...

Lipid metabolism has emerged as a central player in the progression and therapy resistance of breast cancer, particularly the aggressive subtype known as triple-negative breast cancer (TNBC). This ...

The Lipid Market, valued at approximately USD 13.63 billion in 2022, has been witnessing steady growth and is anticipated to maintain a healthy growth rate of more than 6.9% over the forecast period ...

PSORIASIS is a chronic inflammatory skin disease influenced by both genetic and environmental factors, affecting ...

With this vision, Sukh Dev and his team delivered powerful solutions to treat lipid disorders and minimise the risk of early pregnancy loss, and also found cures for parasites plaguing livestock ...

Non-alcoholic fatty liver disease (NAFLD) is a hepatic metabolic syndrome resulting from lipid metabolic imbalance.

This radical new way of the regulation of chloride co-transporter activity linked with membrane lipid expression suggests new therapeutical strategies to treat epilepsy. By increasing the general ...

A breakthrough in safely delivering therapeutic DNA to cells could transform treatment for millions suffering from common chronic diseases like heart disease, diabetes, and cancer. A new process ...